# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹411 Cr** Q3 (+28% YoY) · **₹1,110 Cr** 9M (+14% YoY) * **EBITDA:** **₹115 Cr** Q3 (+41% YoY) · **28%** margin (Q3) · **29%** margin (9M) * **PAT:** **₹55 Cr** Q3 · **₹146 Cr** 9M (~2x FY25 full-year) * **Gross Margin:** **68%** Q3 · **71%** 9M * **ROCE:** **>17%** 9M (ex. Biologics/NBE) vs. 5% in FY23 * **Net Debt:** **₹625 Cr** (as of Dec 31) · **Debt/Equity:** ~25–26% ## B. Revenue Growth * **Record Top-Line Momentum:** Revenue growth sustained across quarters, driven by expansion in core verticals and continued licensing income, supporting confidence in current run rate. * **Diversified Growth Engine:** Business transformation from API-centric to multi-vertical model underpins scalability and reduces reliance on legacy segments. ## C. Margin Expansion * **Margin Leverage Achieved:** EBITDA margin expansion reflects strong operating leverage from higher volumes and fixed-cost absorption. * **High-Quality Gross Margins:** Sustained gross margins above 65% indicate pricing power and favorable product mix in high-margin segments. ## D. Profitability & ROCE * **Capital Efficiency Surge:** Adjusted ROCE more than tripled since FY23, signaling sharp improvement in return profile despite reinvestment in growth verticals. * **Executive Incentive Alignment:** ROCE and market cap are formal KPIs for top management, reinforcing shareholder-value orientation. ## E. Balance Sheet Strength * **Self-Funded Growth Trajectory:** Capex to be met through internal accruals; no major borrowing planned, with net debt expected to trend downward. * **Deleveraging Trend Intact:** Debt-to-EBITDA continues to decline even amid growth investments, reflecting robust cash flow generation. * **Historical Benchmarks Reassessed:** Asset turnover comparisons to pre-diversification era deemed invalid due to structural shift in revenue composition. --- # 2. Product & Segment Performance ## A. Key Figures * **Formulation Revenue:** ₹177 Cr (Q3, +50% YoY) · ₹146 Cr ex-licensing (+104% QoQ) * **API Revenue:** ₹243 Cr (Q3, +11% YoY) · ₹725 Cr (9M, +17% YoY) * **Non-Captive API Revenue:** ₹186 Cr (Q3) * Licensing Income: >40% decline (9M); steady run rate of ~INR150 Cr annually expected ## B. Formulation Business * **Breakout Launch:** NorUDCA exceeds expectations with strong physician uptake and a dual-label strategy driving a healthy order book for upcoming quarters. * **Sustained Momentum:** Three 505(b)(2) products show consistent sequential growth, led by robust volume expansion for Nilotinib in Europe. * **Base Revenue Confirmed:** Management affirms **₹150+ crores** as a sustainable quarterly base for formulation revenues, excluding one-offs. * **Pipeline & Strategy:** Two new formulation products slated for Europe next year; oncology pipeline expanding with multiple products under validation. ## C. API Segment * **Stable CDMO Growth:** Specialty CDMO added three new programs, supporting long-term capacity utilization and margin resilience. * **Captive Leverage:** Total API growth driven by integrated model—captive supply to formulations enhances end-to-end margins and underpins segment performance. ## D. Licensing Income * **Expected Decline:** Licensing income down over 40% YoY due to timing variability in milestones and market conditions, consistent with lumpy revenue profile. ## E. Biologics & NBEs * **Commercial NCE Validation:** First NCE program with U.S. partner successfully commercialized, de-risking the R&D-led model. * **Differentiation Focus:** Strategy emphasizes limited-competition, high-barrier products—exemplified by Nilotinib base innovation and early market entry. * **New Revenue Stream Emerging:** Initial shipments of nontherapeutic albumin to U.S. and U.K. customers yield positive feedback and follow-on demand. --- # 3. R&D & Pipeline Progress ## A. Key Figures * **Pipeline Expansion:** **10 new oncology products** added, including global blockbusters · **3 validated** in the quarter * **Clinical Milestones:** **5 active biologics CDMO programs** with partners · **2 entering Phase I** in next financial year ## B. Clinical Stage Programs * **Phase III Momentum:** Second NCE program in Phase III; Ondansetron long-acting injection filed in India and cleared for commercialization in 1H FY'27, with European trials starting Q4 FY'26. * **High-Potential Biologics:** Aflibercept Phase III ongoing in India, regulatory submission targeted in 1H FY'27; positioned as limited-competition asset with **two key ophthalmic partnerships**. * **NBE & ADC Advancement:** Albumin NBE received global CT protocol approval; IMPD submission expected Q4 FY'26, Phase III trials to begin same quarter despite prior delay; commercialization in India possible by FY'28. * **Next-Gen Pipeline:** SBPL01, first ADC, and two biosimilars to enter human studies in FY'27; Alveolus and mAbTree NBE partnerships also entering Phase I, with **mAbTree product holding orphan designation for two indications**. * **Orphan & Fast Track Assets:** Phase II NCE program holds orphan and Fast Track status across multiple indications; Semaglutide development spans **dual formulations (injectable/oral)** and **synthetic/semisynthetic API routes**, scale-up ongoing for completion by Q4 FY'26–Q1 FY'27. ## C. Regulatory Filings * **D. S. 505(b)(2) Filing Path:** SMLOSD014 completed registration batches, clinical studies to start Q1 FY'27, U.S. filing planned for 2H FY'27. * **CDMO Approval Imminent:** Partnership with Unicycive Therapeutics has resubmitted FDA filing with **PDUFA date of June 29, 2026**, commercialization expected in FY'27. * **EMA Approval Secured:** Rotigotine transdermal patch approved by EMA, launch planned with partner in Q1 FY'27. * **Confidential CDMO Approval:** One CDMO molecule received U.S. FDA approval with commercialization in Q4 FY'26, though specifics withheld due to confidentiality. ## D. New Product Launches * **Rotigotine Launch Confirmed:** First transdermal patch product with marketing authorization secured; launch planned in FY'27, U.S. filing scheduled for Q4 FY'26. ## E. Pipeline Expansion * **Global Ambition for NorUDCA:** Development underway for new indications; human studies in Europe planned for next financial year. * **Strategic Secrecy in Late-Stage Pipeline:** 4–5 advanced products under development with delayed disclosure to avoid competition, mirroring Nilotinib strategy. * **Oncology Innovation Gap Acknowledged:** No new oncology molecule launches in past year outside captive use, despite recent validation of palbociclib and others, with multiple filings expected in next 12 months. --- # 4. Manufacturing & Capacity ## A. Key Figures * Capex: ₹87 Cr incurred in Q3 ## B. Facility Commissioning * **Strategic Facility Milestones:** Three major U.S. NCE and ADC programs advancing, with commercial and GMP facilities set for commissioning in **Q4 FY'26**, including India’s first integrated ADC facility with full payload, linker, and conjugation capabilities. * **Peptide & API Expansion:** Large-scale peptide facility under construction for **GLP-1 products** (liraglutide, semaglutide), targeting global patent expiries in 2–3 years; volume ramp-up from recent API expansions to begin in **Q2 of next fiscal**. * **Formulations Capacity:** New oral solid line recently commissioned, with sufficient headroom for upcoming launches and **additional revenue contribution expected next fiscal**. ## C. Capacity Utilization * **Underutilized Non-Oncology API Capacity:** Current capacity not yet fully leveraged, with **quarter-on-quarter revenue growth expected** as new products ramp up. * **No Peak Revenue Guidance:** Management refrained from providing peak revenue estimates due to **product mix variability**, but emphasized capacity planning for **maximum output efficiency and scalability**. ## D. Peptide & ADC Scale-up * **Advanced Peptide Development:** **API validation batches ongoing for semaglutide**, with **injectable and oral formulations complete**; liraglutide U.S. DMF filed and registration batches underway. * **Robust Peptide Capacity:** Company’s peptide manufacturing capacity exceeds **100 kg**, surpassing estimated needs for high-demand products like semaglutide. ## E. Capex Strategy * **Disciplined Investment Approach:** Shift from long-gestation projects to **high-ROCE, high-IRR initiatives**, avoiding past missteps in transdermal and dispersible film capex. --- # 5. Customer & Market Mix ## A. Key Figures * **Europe Revenues:** **₹73 Cr** (Q) (product sales only) * **Oncology Sales:** ₹116 Cr · ₹141 Cr · ₹111 Cr (last 3 quarters) ## B. Europe & RoW Sales * **Explosive EU Formulation Growth:** Achieved over 100% YoY revenue growth by launching niche, complex products via strategic partners. * **Revenue Recognition Clarity:** Europe and U.S. product sales exclude licensing income; profit share (e.g., Nilotinib) included but recognized with lag, varying by partner. * **Tender-Driven Dynamics:** Nilotinib remains tender-based in Europe with limited generic competition, as innovator holds ~40% share. * **RoW Volatility vs. Long-Term Growth:** Sequential decline in RoW revenues reflects tender timing, but YoY growth remains positive despite quarterly variability.[D] ## C. Oncology Demand Trends * **Oncology Sales Plateau:** Revenue has oscillated around the ₹110–140 Cr range, indicating difficulty in sustaining levels above ₹140–150 Cr. * **NorUDCA Market Potential:** Targets NAFLD, affecting ~25% of Indian patients, representing a substantial domestic opportunity. ## D. Strategic Product Pipeline * **Global Biologics Ambition:** ADC biosimilars and key biologics (including Nivo and Pembro) are being developed for global markets. * **Albumin Opportunity:** Recombinant, purer albumin seen as advantaged in a supply-constrained market, though no financial commitments or size estimates disclosed. ## E. Partner Revenue Recognition * **Exclusive CDMO Partnership:** Company is the sole supplier for a key CDMO molecule, with revenue tracked via quarterly partner updates and minor reconciliations. --- # 6. Risks & Regulatory ## A. Key Figures * **Exceptional Item:** **₹13 Cr** pre-tax charge due to Labour Code changes ## B. FDA Compliance Status * **FDA Resolution in Progress:** All CAPA actions for the Jadcherla facility warning letter have been completed and submitted; awaiting U.S. FDA feedback. ## C. Oncology Filing Delays * **Regulatory Lag in Oncology API:** Company acknowledges delays in DMF filings for key oncology molecules including Palbociclib, Tivozanib, Relugolix, and Ruxolitinib, trailing peer progress. ## D. Labor Code Impact * **One-Time Cost Impact:** Implementation of new Labour Code regulations triggered a ₹13 Cr pre-tax charge, reflecting compliance-related adjustments. --- # 7. Guidance & Outlook ## A. Key Figures * NorUDCA Revenue Potential: Significant opportunity in India and RoW markets for NAFLD, with potential to be a meaningful product * **Licensing Income Run Rate:** **~INR 150 Cr** annually, with recovery to FY '25 levels expected ## B. Launch Timelines * **NorUDCA Revenue Ramp-Up:** Meaningful commercial contribution now expected by **Q4 FY26**, ahead of prior Q1 FY27 outlook, reflecting strong early demand and order book momentum. * **Commercial Partnerships:** Engagement active across **three marketing partners**, with additional partnerships anticipated by **FY '27** to expand market reach. ## C. ROCE Optimization * **Shift to Return-Focused Phase:** Company has exited major capex cycle and is prioritizing **execution, scaling, and ROCE maximization** from existing assets. * **Confidence in Growth Trajectory:** Management cites strong recent growth as evidence of inflection, signaling improved capital efficiency ahead despite absence of formal forecasts.